Announcements Trials
Browse Landscape

Phase

Phase NA 6Phase EARLY_PHASE1 1Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 4Uterine Cervical Neoplasms 1Unresectable Metastatic Colorectal Cancer 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pain, Postoperative 1Ovarian Neoplasms 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Nasopharyngeal Carcinoma 1Lymphatic Metastasis 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Fluorouracil 131Leucovorin 127Oxaliplatin 93Bevacizumab 86Irinotecan 74Capecitabine 63Cetuximab 47Folfox protocol 32Panitumumab 18regorafenib 16trifluridine tipiracil drug combination 15Drug Therapy 14Chemotherapy, Adjuvant 13IFL protocol 10Floxuridine 10Radiotherapy 9Tegafur 7Neoadjuvant Therapy 7Levoleucovorin 7Laparoscopy 7Aspirin 7pembrolizumab 6Trifluridine 6Celecoxib 6atezolizumab 5XELOX 5Mitomycin 5Colonoscopy 5tipiracil 4sintilimab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Colorectal Neoplasms × Control Groups × Clear all
NCT02870582 2022-11-29

Donafenib for Previously Treated Metastatic Colorectal Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Completed
536 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡